SCHEMBL9801476

SCHEMBL9801476

CC1CN(CCO)CCN1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.53
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 1/20 0.39
KMT2A Q03164 3/20 0.33
LMNA P02545 3/20 0.33
OPRM1 P35372 2/20 0.33
OPRD1 P41143 2/20 0.33
OPRK1 P41145 2/20 0.33
OPRL1 P41146 2/20 0.33
HTT P42858 1/20 0.33
KCNH2 Q12809 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
CHRM1 P11229 1/20 0.33
PKM P14618 1/20 0.33
HSD11B1 P28845 1/20 0.33
MEN1 O00255 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
DRD2 P14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9939558 1.00 MAPK1 (0.53) MAPK1ALDH1A1KDM4EKMT2ALMNA
SCHEMBL15312557 1.00 MAPK1 (0.53) MAPK1ALDH1A1KDM4EKMT2ALMNA
SCHEMBL9802128 0.88 MAPK1 (0.42) MAPK1KMT2ALMNAOPRM1MEN1
SCHEMBL7641908 0.81 MAPK1 (0.51) MAPK1ALDH1A1KDM4EKMT2ALMNA
SCHEMBL11957694 0.80 DRD2 (0.41) DRD2DRD3
SCHEMBL11957693 0.80 DRD2 (0.41) DRD2DRD3
SCHEMBL25697929 0.80 MAPK1 (0.35) MAPK1ALDH1A1SMN1; SMN2CHRM1
SCHEMBL9801956 0.80 DRD2 (0.41) DRD2DRD3
SCHEMBL9801141 0.78 ALOX15 (0.50) MAPK1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL9801234 0.78 MAPK1 (0.49) MAPK1ALDH1A1KDM4EKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10669269-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-06-02 US disclosed
US-20180086758-A1 SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2018-03-29 US disclosed
US-9809590-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-11-07 US disclosed
CN-105924437-A Compounds As Type III Receptor Tyrosine Kinase Inhibitors 阵列生物制药公司 2016-09-07 CN disclosed
CN-103347882-B Substituted N- (1H-indazol-4-yl) imidazo [1,2-a ] pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2016-05-11 CN disclosed
US-20160002232-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-01-07 US disclosed
US-9174981-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-11-03 US disclosed
EP-2651939-B1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-04-08 EP disclosed
EP-2651939-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2013-10-23 EP disclosed
US-20130274244-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. 2013-10-17 US disclosed
WO-2012082689-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-06-21 WO disclosed
US-4992150-A Telomer with alpha-olefin;oil and fuel additive NIPPON OIL CO, LTD. (JP) 1991-02-12 US disclosed
US-4781846-A HYDROXYALKYL PIPERAZINE BACTERICIDE IDEMITSU KOSAN LIMITED (JP) 1988-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274244-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS MUSK, FGFR1, FRK MAPK1 223/4885ALDH1A1 2300/4885KDM4E 1691/4885
US-10669269-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors MUSK, FGFR1, PDGFRA MAPK1 179/4885ALDH1A1 1975/4885KDM4E 1837/4885
US-20180086758-A1 SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS LTK, MUSK, FGFR1 MAPK1 378/4885ALDH1A1 2533/4885KDM4E 1420/4885
US-20160002232-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS MUSK, TYRO3, IRAK3 MAPK1 129/4885ALDH1A1 1984/4885KDM4E 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.